Special Drug Use Results Survey of Targretin capsules 75-mg in patients with Cutaneous T-cell Lymphomas

Special Drug Use Results Survey of Targretin capsules 75-mg in patients with Cutaneous T-cell Lymphomas - Targretin Special Drug Use Surveillance (CTCL)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000022568

Enrollment

200

Registered

2016-06-23

Start date

2016-06-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneous T-Cell Lymphomas

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients planning to use Targretin during the enrollment period

Exclusion criteria

Exclusion criteria: No criteria

Design outcomes

Primary

Measure	Time frame
Safety, Efficacy	—

Countries

Japan

Contacts

Public ContactKosuke Shii

Minophagen Pharmaceutical Co., Ltd. Pharmacovigilance Department

gvp@minophagen.co.jp03-5909-2131

Outcome results